A Phase 2/3 interventional study of QRX003-2% Lotion and QRX003-4% Lotion QAM in Netherton Syndrome, sponsored by Quoin Pharmaceuticals. Active, not recruiting at 5 sites in United States. Open to participants aged 14 Years and older. Per ClinicalTrials.gov, last updated 2026-03-16.
Sponsored by Quoin Pharmaceuticals · Phase 2/3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 14 studies in Netherton Syndrome with a site in United States — 4 open to participants now, 6 under way, 4 of them phase 3. Netherton Syndrome · United States.
Among the 14 studies in Netherton Syndrome with a site in United States, this one is the 4th largest by planned enrollment of the 12 interventional ones that give a count, is one of 3 that started in 2022, is one of 5 in phase 2/3, and was the 6th registered.
22 studies on the registry are indexed under Netherton Syndrome; 5 are open to participants now.
Browse Netherton Syndrome studies →4 of the 14 studies in Netherton Syndrome with a site in United States are open now. Recruiting first, the newest first:
Quoin Pharmaceuticals · Sites in United States, United Kingdom
Ages 4+
Quoin Pharmaceuticals · Sites in United States
Ages 14+
Quoin Pharmaceuticals · Sites in United States
Ages 14+
Northwestern University · Sites in United States
Ages 1–60 · Healthy volunteers
A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →
Of the 4 Netherton Syndrome studies recruiting now, 4 set no upper age limit and none stop at 75 or younger; 4 take children under 18; none take healthy volunteers.
This study: 14 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
14 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 6 · Phase 2 7 · Phase 3 5
First in 2005; this study’s year is marked. 3 started in 2022.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 30 is above the median of 16 across 19 interventional studies indexed under Netherton Syndrome.
Median enrollment 20 across the 12 interventional studies, 102 across the 2 observational. Of the 8 that completed or were terminated, 4 (50%) have results posted.
This tab as a report to print or save as PDF → With an account.
11 of 14 have an industry lead sponsor. The 8 most frequent:
Quoin Pharmaceuticals is the lead sponsor of 4 studies on the registry; 3 are open to participants now.
Quoin Pharmaceuticals has 4 studies filed under Netherton Syndrome — fewer than ten, so there is no comparison to draw.
4 of the studies in Netherton Syndrome with a site in United States that are under way reach primary completion within a year, 3 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT05789056Phase 3Quoin PharmaceuticalsOpen Label, Safety and Efficacy Study of QRX003 Lotion in Subjects With Netherton Syndrome | 2026-12-30 |
| NCT06953466Phase 3Quoin PharmaceuticalsClinical Study of QRX003 Lotion in Subjects With Netherton Syndrome | 2026-12-30 |
| NCT07538583Phase 3Quoin PharmaceuticalsPhase 2/3 Clinical Study of QRX003 Lotion in Subjects With Netherton Syndrome | 2027-01-31 |
| NCT06539507BioCryst PharmaceuticalsA Study of the Safety, Tolerability, Pharmacokinetics, and Immunogenicity of BCX17725 | 2026-12 |
Add all 4 to your calendar (.ics) → With an account.
Among the 14 studies in Netherton Syndrome with a site in United States, from their registry updates:
This tab as a report to print or save as PDF → With an account.
This study has been designed to determine the safety, tolerability and efficacy of QRX003 lotion 2%, 4% QAM or 4% BID in subjects with Netherton Syndrome (NS) in comparison to vehicle
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.
The study may name a correction formula and a limit in milliseconds, often around 450–480.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Postmenopausal
Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
QT and QTc
On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.
The study may name a correction formula and a limit in milliseconds, often around 450–480.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis B tests
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Subjects will apply test article once daily in the morning (QAM) for 12 weeks
Drug: QRX003-2% Lotion
Subjects will apply test article once daily in the morning (QAM) for 12 weeks
Drug: QRX003-4% Lotion QAM
Subjects will apply test article once daily in the morning (QAM) for 12 weeks
Drug: Vehicle
Subjects will apply test article twice daily BID for 12 weeks
Drug: QRX003-4% Lotion BID
QRX003Topical Lotion containing 2% active drug (serine protease inhibitor)
QRX003Topical Lotion containing 4% active drug (serine protease inhibitor)
Vehicle Lotion
QRX003Topical Lotion containing 4% active drug (serine protease inhibitor)
Efficacy Endpoints-1-point IGA
Proportion of subjects with 1-point reduction on the Investigator's Global Assessment (IGA) from Baseline. The IGA assesses overall severity of a subject's NS based on a 5-point scale where 0 = clear, 1 = almost clear, 2 = mild, 3 = moderate, and 4 = severe.
Time frame: Up to week 16
Efficacy Endpoints-2-point IGA
Proportion of subjects with 2-point reduction in IGA from Baseline.
Time frame: Up to week 16
Efficacy Endpoints-NS Sign
Change from Baseline in each individual NS Sign (erythema and scaling). Severity of each NS sign is graded on a 5-point scale.
Time frame: Up to week 16
Efficacy Endpoints-BSA
Change from Baseline in total Body Surface Area (BSA) affected by NS in the Treatment Area
Time frame: Up to week 16
Efficacy Endpoints-WI-NRS score
Change from Baseline in the Worst Itch-Numeric Rating Scale (WI-NRS) score. Itch severity is graded on an 11-point scale where 0 represents "no itch" and 10 represents "worst itch imaginable".
Time frame: Up to week 16
Efficacy Endpoints-TSQM
Assessment of subject satisfaction with treatment based on the Treatment Satisfaction Questionnaire for Medication (TSQM). The TSQM measures a subject's level of satisfaction or dissatisfaction with the treatment. Composite scores can range from 0 to 100; higher scores indicate better satisfaction.
Time frame: Up to week 16
Efficacy Endpoints-Rescue Therapy
Proportion of subjects requiring rescue therapy
Time frame: Up to week 16
Safety Endpoints-AEs
Any local and systemic AEs (Adverse Events)/serious AEs
Time frame: Up to week 16
Safety Endpoints-LSR
Number of subjects with presence of the following LSRs (Local Skin Reactions): edema, excoriations, oozing/vesiculation/crusting, and erosions at any study visit.
Time frame: Up to week 16
Plan to share: No
No publications or documents are linked to this record.
Ran from Jun 2022 to primary completion in Dec 2025, 42 months.
How these figures are worked out, and which studies are left out of them.
This study is active, not recruiting, as verified in Mar 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: QRX003
Quoin Pharmaceuticals